After an initial ~12-month period of treatment, long-term strategies to maintain a healthy weight include: Personalised treatment plans and regular follow-up are key to preventing rebound weight gain
Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, et al
The Future of GLP-1 Medications As demand for GLP-1 receptor agonists continues to grow, questions remain about their role in healthcare
Oral semaglutide (wegovy) 50 mg in summary 15% average body weight reduction in obesity studies (e.g., OASIS trials)
Many large employer groups have included weight-loss drug coverage in their Kaiser plans starting in 2024 and 2025 as GLP-1 coverage became a benefits competitive issue
PlexusDx delivers compounded semaglutide injections through licensed 503A pharmacies with straightforward weekly dosing instructions